multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Definition

  • A bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion

Signs and Symptoms

  • Patients usually present w/ bone pain & fatigue due to anemia
  • Nonspecific symptoms eg nausea, vomiting, malaise, weight loss, generalized body weakness, fatigue

Etiology

  • There are 2 processes being considered to be the root cause of multiple myeloma

Premalignant Stage: Appearance of MGUS

  • Brought about by the cytogenic abnormalities &/or abnormal cellular response to an antigenic stimulus
  • Malignant transformation of plasma cells leads to production of monoclonal paraprotein (M-protein) composed of single heavy & light chain immunoglobulins
    • Abnormal immunoglobulins include IgG, IgM, IgA, & rarely IgE & IgD
    • Light chain protein κ & λ are also seen
    • These immunoglobulins cause hyperviscosity & end-organ damage
  • Chromosomal aberrations identified w/ multiple myeloma include del17p13, IgH gene rearrangement at 14q32, 14q32 translocations [t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q32;q23), t(14;20)(q32;q12)], & chromosome 1 abnormalities
    • These aberrations lead to the development of plasma cell clones 
  • An antigenic stimulus when interpreted by cells [eg toll-like receptors (TLRs) on myeloma cells, interleukin-6 (IL-6)] abnormally causes an increase in plasma cells, thereby causing chromosomal changes leading to plasma cell clones & abnormally produced immunoglobulins

Disease Progression from MGUS to Multiple Myeloma

  • Triggering factors that contribute to the development of MGUS into multiple myeloma include secondary cytogenic aberrations (secondary IgH translocation, Ras mutations, activation of the NF κ B pathway), abnormalities in the cell cycle pathway, interrupted apoptosis, & various factors affecting the bone marrow

Risk Factors

  • Age (increases risk)
  • Immunosuppression
  • Environmental exposures
  • Gender (more common in men)
  • Occupational exposure to toxic substances such as radiation, solvents, herbicides, insecticides

Epidemiology

  • Accounts for 1-2% of all cancers worldwide
    • 2nd most frequent hematologic malignancy in the US, w/ rapidly increasing incidence rate in Asia
  • Median age of onset is 66 years old

Pathophysiology

  • Always preceded by a premalignant stage, monoclonal gammopathy of undetermined significance (MGUS)
    • Only 10% of patients w/ newly diagnosed multiple myeloma have a history of pre-existing MGUS since patients w/ MGUS are asymptomatic
    • Rate of progression of MGUS to multiple myeloma is 1% per year
    • Non-IgM immunoglobulin MGUS (non-IgM MGUS) makes up 80% of premalignant multiple myeloma
    • Light-chain immunoglobulin MGUS makes up 20% of premalignant multiple myeloma
    • IgM immunoglobulin MGUS usually develops into Waldenström macroglobulinemia but may rarely evolve into multiple myeloma (IgM myeloma)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 13 May 2019

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.